

# CONTENTS

---

<b>PREFACE</b>	<b>xiii</b>
<b>LIST OF CONTRIBUTORS</b>	<b>xv</b>
<b>PART I. INTRODUCTION</b>	<b>1</b>
<b>1. Historical Perspective</b>	<b>3</b>
<i>Roberta S. King</i>	
1.1 Controversies Spanning Past, Present, and Future	3
1.2 1800s: Discovery of Major Drug Metabolism Pathways (Conti and Bickel, 1977)	4
1.3 1900–1950s: Confirmation of Major Pathways and Mechanistic Studies	7
1.4 1950s–1980: Modern Drug Metabolism Emerges, with Enzymatic Basis	8
1.5 1980–2005: Field Driven by Improved Technologies	9
1.6 2005+: High Technology	9
Acknowledgments	10
References	10
<b>2. Factors Affecting Metabolism</b>	<b>13</b>
<i>Roberta S. King</i>	
<b>3. Biotransformations in Drug Metabolism</b>	<b>17</b>
<i>Roberta S. King</i>	
3.1 Drug Metabolism in Drug Development and Drug Therapy	17
3.2 Prediction of Metabolite and Responsible Enzyme	20
3.3 Functional Group Biotransformations: Phase I, Phase II, Catalysis	20
3.4 Oxidations and Cytochrome P450	23
3.5 Enzymology and Modifiers of CYPs	34
References	38
<b>4. In Vivo Metabolite Kinetics</b>	<b>41</b>
<i>Zheng Yang</i>	
4.1 Introduction	41
4.2 <i>In Vivo</i> Metabolite Kinetic Concepts and Principles	42
4.3 Effect of Inhibition and Induction on Metabolite Kinetics	55
4.4 Determination of Formation and Elimination Clearance of Metabolite	60
4.5 Summary	62

Acknowledgments	62
References	62
<b>5. Pharmacogenetics and Pharmacogenomics</b>	<b>65</b>
<i>Lilian G. Yengi</i>	
5.1 Introduction: Pharmacogenetics and Pharmacogenomics	65
5.2 Pharmacogenomics of Drug-Metabolizing Enzymes (DME)	66
5.3 Polymorphisms in Genes Encoding DME and Implications for Drug Discovery and Development	67
5.4 Applications of Genetics and Genomics in Drug Discovery and Development	75
References	77
<b>6. Introduction to Drug Transporters</b>	<b>89</b>
<i>Louis Leung and Aram Oganessian</i>	
6.1 Introduction	89
6.2 Transporter Classification, Localization, and Functions	89
6.3 Clinical Drug–Drug Interactions	99
6.4 Polymorphisms and Regulation of Drug Transporters	106
6.5 <i>In Vitro</i> Methods in Evaluation of Drug Transporters	107
6.6 Transporters–Drug-Metabolizing Enzymes Interplay	109
6.7 Outlook	110
References	111
<b>PART II. TECHNOLOGIES FOR <i>IN VITRO</i> AND <i>IN VIVO</i> STUDIES</b>	<b>127</b>
<b>7. Automated Drug Screening for ADMET Properties</b>	<b>129</b>
<i>Melvin Reichman and Helen Gill</i>	
7.1 Introduction	129
7.2 Background	129
7.3 Modern Laboratory Automation: Origins in ADMET	132
7.4 Computational Chemistry 101: The Lipinski Rules	134
7.5 Automated Methods for Determining log P/log D	135
7.6 Drug Solubility	137
7.7 Drug Permeability	141
7.8 Drug Transporters in Intestinal Absorption	146
7.9 Drug Metabolism	147
7.10 Plasma Protein Binding	158
7.11 QC/QA Considerations	160
7.12 Summary	161
References	162
<b>8. Mass Spectrometry</b>	<b>167</b>
<i>Thomas R. Sharp</i>	
8.1 Introduction	167
8.2 A Brief History	168

8.3	General Background in Mass Spectrometry	170
8.4	Instrumentation	172
8.5	Inlet Systems: Getting Samples In	173
8.6	Ionization Methods: Making Ions	179
8.7	Mass Analysis: Sorting by Size	188
8.8	Detection: Seeing What Has Been Generated	190
8.9	Interpretation of Mass Spectral Data	192
	References	221
<b>9.</b>	<b>Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and Development</b>	<b>229</b>
	<i>Ala F. Nassar</i>	
9.1	Introduction	229
9.2	Criteria for LC-MS Methods	231
9.3	Matrices Effect	231
9.4	Metabolite Characterization	232
9.5	Strategies for Identifying Unknown Metabolites	235
9.6	“All-in-One” Radioactivity Detector, Stop Flow, and Dynamic Flow for Metabolite Identification	242
9.7	Strategies to Screen for Reactive Metabolites	247
9.8	Summary	248
	References	249
<b>10.</b>	<b>Structural Modifications of Drug Candidates: How Useful Are They in Improving Metabolic Stability of New Drugs? Part I: Enhancing Metabolic Stability</b>	<b>253</b>
	<i>Ala F. Nassar</i>	
10.1	Background	253
10.2	Introduction	254
10.3	Significance of Metabolite Characterization and Structure Modification	255
10.4	Part I: Enhance Metabolic Stability	255
10.5	Metabolic Stability and Intrinsic Metabolic Clearance	256
10.6	Advantages of Enhancing Metabolic Stability	257
10.7	Strategies to Enhance Metabolic Stability	257
10.8	Conclusions	265
	References	266
<b>11.</b>	<b>Structural Modifications of Drug Candidates: How Useful Are They in Improving PK Parameters of New Drugs? Part II: Drug Design Strategies</b>	<b>269</b>
	<i>Ala F. Nassar</i>	
11.1	Introduction	269
11.2	Active Metabolites	269
11.3	Prodrugs	273
11.4	Hard and Soft Drugs	274
11.5	PK Parameters	275
11.6	PK Analysis	278

11.7	Conclusions	278
	References	280
<b>12.</b>	<b>Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development</b>	<b>283</b>
	<i>Ala F. Nassar</i>	
12.1	Introduction	283
12.2	Idiosyncratic Drug Toxicity and Molecular Mechanisms	287
12.3	Key Tools and Strategies to Improve Drug Safety	290
12.4	Peroxidases	295
12.5	Acyl Glucuronidation and <i>S</i> -acyl-CoA Thioesters	295
12.6	Covalent Binding	296
12.7	Mechanistic Studies	298
12.8	Preclinical Development	300
12.9	Clinical Development: Strategy	301
12.10	Conclusion and Future Possibilities	302
	References	302
<b>13.</b>	<b>Screening for Reactive Metabolites Using Genotoxicity Arrays and Enzyme/DNA Biocolloids</b>	<b>307</b>
	<i>James F. Rusling, Eli G. Hvastkovs, and John B. Schenkman</i>	
13.1	Introduction	307
13.2	Electrochemical and Electrochemiluminescent Arrays	310
13.3	DNA/Enzyme Biocolloids for LC-MS Toxicity Screening	318
13.4	Alternative Arrays and Other Novel Approaches	325
13.5	Summary and Future Outlook	332
	References	333
<b>PART III.</b>	<b>DRUG INTERACTIONS</b>	<b>341</b>
<b>14.</b>	<b>Enzyme Inhibition</b>	<b>343</b>
	<i>Paul F. Hollenberg</i>	
14.1	Introduction	343
14.2	Mechanisms of Enzyme Inhibition	345
14.3	Competitive Inhibition	345
14.4	Noncompetitive Inhibition	347
14.5	Uncompetitive Inhibition	348
14.6	Product Inhibition	348
14.7	Transition-State Analogs	349
14.8	Slow, Tight-Binding Inhibitors	349
14.9	Mechanism-Based Inactivators	349
14.10	Inhibitors That Are Metabolized to Reactive Products That Covalently Attach to the Enzyme	352
14.11	Substrate Inhibition	352
14.12	Partial Inhibition	353
14.13	Inhibition of Cytochrome P450 Enzymes	353

14.14	Reversible Inhibitors	354
14.15	Quasi-Irreversible Inhibitors	355
14.16	Mechanism-Based Inactivators	356
	References	357
<b>15.</b>	<b>Evaluating and Predicting Human Cytochrome P450 Enzyme Induction</b>	<b>359</b>
	<i>Michael Sinz, Sean Kim, Stephen Ferguson, and Edward LeCluyse</i>	
15.1	Introduction	359
15.2	Receptor-Based <i>In Vitro</i> Bioassays	361
15.3	Immortalized Hepatocytes	364
15.4	HepG2 and HepG2-Derived Cell Lines	364
15.5	HBG-BC2	365
15.6	Hepatocarcinoma-Derived Cell Line: HepaRG	366
15.7	Cells of Intestinal Origin: LS180 and Caco-2	366
15.8	Immortalized Human Hepatocyte Cell Lines: Fa2N-4	367
15.9	Other Immortalized Hepatocyte Cell Lines	368
15.10	Primary Human Hepatocyte Culture Systems	368
15.11	Interpretation and Quantitative Prediction of Enzyme Induction	373
15.12	Clinical Drug Interaction Studies	375
15.13	Industrial and Regulatory Perspectives	377
15.14	Future Models	378
15.15	Conclusions	380
	Acknowledgments	381
	References	381
<b>16.</b>	<b>An Introduction to Metabolic Reaction Phenotyping</b>	<b>391</b>
	<i>Carl D. Davis and A. David Rodrigues</i>	
16.1	Introduction	391
16.2	Drug Metabolism	391
16.3	Objectives of Reaction Phenotyping in Drug Discovery	393
16.4	Metabolic Stability Screening	393
16.5	Drug-Metabolizing Enzymes	394
16.6	Assay Optimization for Metabolic Clearance and Reaction-Phenotyping Studies	404
16.7	<i>In Vitro</i> to <i>In Vivo</i> Extrapolation of Metabolic Clearance	413
16.8	<i>In Vitro</i> to <i>In Vivo</i> Extrapolation and Physiological Models of Hepatic Clearance	419
16.9	Summary	435
	Acknowledgment	436
	References	436
	Further Reading	446
<b>17.</b>	<b>Nuclear Receptor-Mediated Gene Regulation in Drug Metabolism</b>	<b>449</b>
	<i>Hongbing Wang and Wen Xie</i>	
17.1	Introduction	449
17.2	Pregnane X Receptor	451
17.3	Constitutive Androstane/Activated Receptor (CAR)	461

17.4	Aryl Hydrocarbon Receptor (AhR)	470
17.5	Closing Remarks and Perspectives	470
	Acknowledgments	471
	References	471
<b>18.</b>	<b>Characterization of Cytochrome P450 Mechanism-Based Inhibition</b>	<b>479</b>
	<i>Dan Rock and Larry C. Wienkers</i>	
18.1	Introduction	479
18.2	Inhibitors That upon Activation, Bind Covalently to the P450 Apoprotein	488
18.3	Inhibitors That Interact in a Pseudo-Irreversible Manner with Heme Iron	489
18.4	Inhibitors That Cause Destruction of the Prosthetic Heme Group, Oftentimes Leading to Heme-Derived Products That Covalently Modify the Apoprotein	491
	References	524
<b>19.</b>	<b>Clinical Drug–Drug Interactions</b>	<b>535</b>
	<i>Sujal V. Deshmukh</i>	
19.1	Introduction	535
19.2	Mechanisms of DDIs	537
19.3	Avoiding DDI	543
	References	543
	Further Reading	546
<b>20.</b>	<b>Pharmaceutical Excipients in Drug–Drug Interaction</b>	<b>547</b>
	<i>Chuan Chen and Abu J.M. Sadeque</i>	
20.1	Introduction	547
20.2	Interaction of Pharmaceutical Excipients with Cytochrome P450s (CYPs)	548
20.3	Interaction of Pharmaceutical Excipients with Transporters	552
20.4	Summary	554
	References	555
<b>PART IV.</b>	<b>TOXICITY</b>	<b>559</b>
<b>21.</b>	<b>The Role of Drug Metabolism in Toxicity</b>	<b>561</b>
	<i>Carl D. Davis and Umesh M. Hanumegowda</i>	
21.1	Introduction	561
21.2	Drug-Metabolizing Enzymes	562
21.3	Classification of Toxicity	581
21.4	Molecular Mechanisms of Toxicity	582
21.5	Organ Systems Toxicology	588
21.6	Carcinogenesis	599
21.7	Teratogenesis	601

21.8	Abrogation/Mitigation of Bioactivation—Case Examples	602
21.9	Experimental Methods for Screening	605
21.10	Summary	606
	Acknowledgment	608
	References	608
<b>22.</b>	<b>Allergic Reactions to Drugs</b>	<b>629</b>
	<i>Mark P. Grillo</i>	
22.1	Introduction	629
22.2	Immune System: A Brief Overview	630
22.3	Drug Metabolism and the Hapten Hypothesis	631
22.4	Allergic Reactions to Drugs (Examples)	632
22.5	Conclusions	644
	Acknowledgments	646
	References	646
<b>23.</b>	<b>Chemical Mechanisms in Toxicology</b>	<b>655</b>
	<i>Mark P. Grillo</i>	
23.1	Introduction	655
23.2	Glutathione Adducts	659
23.3	Covalent Binding	662
23.4	Structural Alerts	663
23.5	Examples of Metabolic Activation	664
23.6	Conclusions	685
	Acknowledgments	687
	References	687
<b>24.</b>	<b>Mechanisms of Reproductive Toxicity</b>	<b>697</b>
	<i>Aileen F. Keating and Patricia B. Hoyer</i>	
24.1	Introduction	697
24.2	Overview—Female Reproduction	698
24.3	Overview—Male Reproduction	701
24.4	Sites of Targeting and Outcomes	704
24.5	Effects of Specific Chemicals	708
24.6	Translational Applications	721
24.7	Conclusions and Future Directions	723
	References	724
<b>25.</b>	<b>An Introduction to Toxicogenomics</b>	<b>737</b>
	<i>Aaron L. Vollrath and Christopher A. Bradfield</i>	
25.1	Introduction	737
25.2	Microarrays: Genomics-Based Methods for Transcriptional Profiling	737
25.3	Chemical Classification—Identifying Chemically Induced Signatures and Their Potential Use in Risk Assessment	738
25.4	Experimental Designs of Microarray-Based Technologies	744

25.5	The Interpretation and Analysis of Data Generated by Microarray Methodologies	747
25.6	Four Basic Microarray-Based Approaches	748
25.7	Informatics Tools Utilized by These Informatics Approaches	755
25.8	Conclusion	755
	References	756
<b>26.</b>	<b>Role of Bioactivation Reactions in Chemically Induced Nephrotoxicity</b>	<b>761</b>
	<i>Lawrence H. Lash</i>	
26.1	Overview of Renal Structure and Function: Toxicological Implications	761
26.2	Interorgan and Intra-renal Bioactivation Pathways	762
26.3	Cytochrome P450 (CYP)-Dependent Bioactivation in Renal Proximal Tubular Cells	765
26.4	Flavin-Containing Monooxygenase (FMO)-Dependent Bioactivation in Renal Proximal Tubular Cells	767
26.5	Renal Bioactivation of Cysteine Conjugates: GSH Conjugation as a Bioactivation Rather Than a Detoxication Pathway	768
26.6	Renal Bioactivation of Acetaminophen	775
26.7	Summary and Conclusions	776
	References	777
<b>PART V.</b>	<b>REGULATORY PERSPECTIVES</b>	<b>783</b>
<b>27.</b>	<b>Drug Metabolism in Regulatory Guidances, Clinical Trials, and Product Labeling</b>	<b>785</b>
	<i>Mark N. Milton</i>	
27.1	Introduction	785
27.2	The Regulatory Environment	786
27.3	Background Information in Regulatory Guidances	795
27.4	Nonclinical Guidances and Early-Stage Drug Development	798
27.5	Clinical Guidances and Clinical Trials	858
27.6	Biologics	948
27.7	Miscellaneous Topics	955
27.8	Product Labeling	959
27.9	Procedural Guidances	974
27.10	Initiatives from Regulatory Agencies	980
27.11	Summary	982
	References	982
<b>INDEX</b>		<b>1001</b>